Apogee Therapeutics Surges to Record $133 on $10.9 Billion AbbVie Acquisition on Monday
According to AbbVie's announcement, Apogee Therapeutics (APGE) stock hit a record high of $133 on Monday (June 23) after the pharmaceutical giant agreed to acquire the biotechnology company for $135.11 per share in an all-cash deal valued at approximately $10.9 billion. The acquisition targets Apoge
GateNews·06-23 03:14
